@Peter_Grinspoon @drstacigruber Thank you. This paper - data from 54 patients- doesn’t speak to the suitability - or lack thereof- of using CUDIT-R criteria to determine problematic medical cannabis use. Questions it in the discussion I’m sure you’ve loo
@daishan79 @brianpelletier @DrScottHadland That’s your opinion. There are other studies on the risk of problematic prescription cannabinoids you may find interesting. Happy reading! 👋🏽 https://t.co/vpfWyg2iLq
So in short, We need to monitor high risk patients, but over all no signs of addiction. #potnotpills #SpreadLove #stonerfam @HIGH_TIMES_Mag @Leafly @NORML @stevedeangelo @AlexisBortell @edrosenthal @BizCannabis @VeteransAnanda @Andrew_DeAngelo @NorCalStone
@tomfolanmd @drstacigruber @CannMedEvents @camaccallum @healercom_ Reminds me of @drmarkaware's paper https://t.co/ypOkBrMOWp
@Icetender65Mike @JodieEmery I treat pain with cannabis. So I have tried. And as for safety in the context of medical use, we don't know enough yet, but some data is starting to come out. At the end of the day, its about the patient in front of you https:
RT @drpaolandmd: When talking with physicians about #medicalcannabis, one of the most commonly asked questions is the proportion of patient…
RT @drpaolandmd: When talking with physicians about #medicalcannabis, one of the most commonly asked questions is the proportion of patient…
RT @drpaolandmd: When talking with physicians about #medicalcannabis, one of the most commonly asked questions is the proportion of patient…
When talking with physicians about #medicalcannabis, one of the most commonly asked questions is the proportion of patients that may engage in problematic use. This study by @drmarkaware and colleagues sheds some light on this issue https://t.co/wmnwyRY3
roughly 25% of patients demonstrated PPCBU https://t.co/KNUk3e15WX